(VIANEWS) – LNA SANTE (LNA.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| LNA SANTE (LNA.PA) | €29.75 | 1.98% | 9.08% |
| EUROFINS SCIENT. (ERF.PA) | €56.30 | 1.81% | 9.12% |
| EQUASENS (EQS.PA) | €74.70 | 1.53% | 26.83% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. LNA SANTE (LNA.PA)
1.98% Forward Dividend Yield and 9.08% Return On Equity
LNA Santé SA engages in the management and operation of health establishments. The company operates retirement homes, medical and rehabilitation care, home hospital, mental health clinic, and health center. LNA Santé SA was founded in 1990 and is based in Vertou, France.
Earnings Per Share
As for profitability, LNA SANTE has a trailing twelve months EPS of €2.39.
PE Ratio
LNA SANTE has a trailing twelve months price to earnings ratio of 12.45. Meaning, the purchaser of the share is investing €12.45 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.08%.
Yearly Top and Bottom Value
LNA SANTE’s stock is valued at €29.75 at 07:30 EST, way under its 52-week high of €34.00 and way higher than its 52-week low of €24.50.
Revenue Growth
Year-on-year quarterly revenue growth grew by 1.1%, now sitting on 732.02M for the twelve trailing months.
Volatility
LNA SANTE’s last week, last month’s, and last quarter’s current intraday variation average was a negative 1.21%, a negative 0.95%, and a positive 1.46%.
LNA SANTE’s highest amplitude of average volatility was 1.35% (last week), 1.64% (last month), and 1.46% (last quarter).
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, LNA SANTE’s stock is considered to be overbought (>=80).
More news about LNA SANTE.
2. EUROFINS SCIENT. (ERF.PA)
1.81% Forward Dividend Yield and 9.12% Return On Equity
Eurofins Scientific SE, together with its subsidiaries, provides various analytical testing and laboratory services worldwide. The company offers a portfolio of approximately 130,000 analytical methods to evaluate the safety, identity, composition, authenticity, origin, traceability, and purity of various products. It provides services such as agroscience, including biological assessment, consumer and human, and environmental safety, product chemistry, regulatory consultancy, and seed services; agro testing; assurance, such as product inspection, auditing, certification, training and consultation of food, consumer products, and healthcare and cosmetics; biopharma, and clinical diagnostics. In addition, the company offers consumer product testing, which include product compliance and audit, testing, certifications and approvals, inspections, training courses, and digital media and cyber security for various industries; cosmetics and personal care; environment testing, including water, air, soil, waste, and other products testing; and food and feed testing that include allergen, GMO, grain, meat, nano material, pesticides, and residual DNA testing. Further, it offers audit and certification, training and consulting; and testing for persistent organic pollutants, dioxins and organic contaminants, pesticides, mycotoxins, allergens, and pathogens and vitamins, as well as analyses for genetic modifications. Additionally, the company provides forensic, genomic, maritime, materials and engineering, REACH, and technologies services. The company was founded in 1987 and is headquartered in Luxembourg City, Luxembourg.
Earnings Per Share
As for profitability, EUROFINS SCIENT. has a trailing twelve months EPS of €2.28.
PE Ratio
EUROFINS SCIENT. has a trailing twelve months price to earnings ratio of 24.69. Meaning, the purchaser of the share is investing €24.69 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 9.12%.
Yearly Top and Bottom Value
EUROFINS SCIENT.’s stock is valued at €56.30 at 07:30 EST, way below its 52-week high of €72.64 and above its 52-week low of €52.78.
Volatility
EUROFINS SCIENT.’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.85%, a negative 0.32%, and a positive 1.12%.
EUROFINS SCIENT.’s highest amplitude of average volatility was 0.85% (last week), 0.90% (last month), and 1.12% (last quarter).
Moving Average
EUROFINS SCIENT.’s value is under its 50-day moving average of €57.35 and below its 200-day moving average of €61.56.
More news about EUROFINS SCIENT..
3. EQUASENS (EQS.PA)
1.53% Forward Dividend Yield and 26.83% Return On Equity
Equasens Société anonyme provides various IT solutions for the healthcare sector in Europe. It offers LGPI global services and OffiCentral solutions for managing pharmacies and their networks; OffiMSS, OffiSecure, OffiProtect, OffiPass, OffiSeen, OffiCash, Offizzy, and OffiLocker solutions for pharmacists' business processes; and solutions for energizing the customer relationship with pharmacists comprising OffiTag, OffiTouch, OffiMédia, OffiConnect, automation systems, and customer loyalty programs. The company also provides My Pilot, an analytics and management tool; OffiLearning, an e-learning tool; and solutions for patient support and advice, such as compliance monitoring software, Multimeds, Automeds, and OffiTéléconsult, as well as pharmaceutical record and shared medical record services. In addition, it offers a ULTIMATE, a system combining optimized pharmacy management and improved patient support; FARMACLICK, a protocol for communications between pharmacies and wholesalers-distributors; DIFARM, a solution for wholesalers-distributors; PHARE, a retail management tool; SOPHIA, a pharmacy management application; OffiMédia POS display; eNephro to enhance the care of chronic renal failure patients; and TPE Pilot, a web-based application that simplifies the management and sharing of patient education programs. Further, the company provides NOVIACARE; CARELIB Domicile; CARELIB EHPAD; KAPELSE solutions; TITAN solutions; ANTHADINE software and MOBISOINS mobile tool; MICROSOINS, an in-home nursing care solution; and LOGICLIC. Additionally, it offers AXIGATE solutions to manage the entire patient care pathway; CHORUS platform; medical telesecretarial services for healthcare professionals; and equipment lease financing solutions. The company was incorporated in 1996 and is based in Villers-les-Nancy, France. Equasens Société anonyme is a subsidiary of Marque Verte Sante.
Earnings Per Share
As for profitability, EQUASENS has a trailing twelve months EPS of €3.05.
PE Ratio
EQUASENS has a trailing twelve months price to earnings ratio of 24.49. Meaning, the purchaser of the share is investing €24.49 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 26.83%.
Volatility
EQUASENS’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.93%, a negative 0.19%, and a positive 1.01%.
EQUASENS’s highest amplitude of average volatility was 2.20% (last week), 0.90% (last month), and 1.01% (last quarter).
More news about EQUASENS.
